2ml vial of tirzepatide Eli Lilly Launches Self-Pay Vials for Patients With Obesity Vial math- Help me understand

Navigating Different Scenarios: When It's Covered vs

Behavioral prompts target emotional eating and help you practice stress-reducing movement breaks

annual subscription: $3,866 ($322/month) Monthly semaglutide: $249/month

GIP receptor activation appears to enhance insulin release in a glucose-dependent manner, complementing GLP-1s effects and potentially reducing the risk of hypoglycemia in certain models

LillyDirect Self-Pay: The Manufacturer Cash Program Eli Lilly offers a direct-to-consumer self-pay program for Zepbound only

Tell your provider if you have a history of pancreatitis, diabetic retinopathy (vision changes), hypoglycemia (low blood sugar), kidney problems, gallbladder disease, or an allergy to any active ingredients in the tirzepatide or semaglutide product